knowledge -WSS

knowledge

author：fashion 2025-09-29 16:35:25 - browse：91

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Paxlovid should be available without a positive Covid test

WSS

Flu, Covid vaccination rates decline, new survey data show

FDA seeks to regulate lab

CDC picks Alphabet's Verily for wasterwater surveillance contract

Researchers use wearables data and AI to predict preterm birth risk

WHO recommends dropping component of many flu vaccines

Menendez indictment could see pharma lose a key ally

hotspot

knowledge

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

The stability of $0 premiums in Medicare Advantage

At least 13 dead in Texas as scorching temps continue

After a drawn out lobbying fight, ARPA

Trump demands the U.S. pay no more for drugs than other countries … again

Menendez indictment could see pharma lose a key ally

Moonlake's readout produced a cash windfall. Risks remain

After a drawn out lobbying fight, ARPA

United colonoscopy coverage change 'may cost lives,' doctors say

CDC picks Alphabet's Verily for wasterwater surveillance contract

Wikipedia

Medicare innovation center doesn’t save money, experts say

WHO recommends dropping component of many flu vaccines

Medicare innovation center doesn’t save money, experts say

Listen: Who gets the credit for GLP

With Roe v Wade overturned, abortion providers work to adapt

2023 Nobel Prize in Medicine goes to Karikó and Weissman

leisure time

focus

explore

Wikipedia